RxDoctor Payments Data

Brian Friedrich, DO

Internal Medicine · Drexel Hill, PANPI 1952455701

Payments from drug & device makers

$1,230in general payments, 2019–2025

Across 74 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$262
  • Lilly USA, LLC$200
  • AbbVie$122
  • Johnson & Johnson$116
  • Astellas Pharma US Inc$96
  • UCB, Inc.$78
  • plus $355 from 10 others

What the payments were for

  • Food & beverage$1,21799%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,230 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,460
Medicare patients
80
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriparatide41$87,324
NuedextaDextromethorphan Hbr/Quinidine30$45,318
EliquisApixaban60$33,956
Lacosamide117$33,609
LinzessLinaclotide48$27,597
JanuviaSitagliptin Phosphate49$27,385
VemlidyTenofovir Alafenamide17$25,233
CreonLipase/Protease/Amylase14$24,892
Aripiprazole140$20,769
Entecavir20$17,568
BriviactBrivaracetam12$17,304
Budesonide39$16,657
RexultiBrexpiprazole11$14,677
Cinacalcet Hcl24$13,829
Levetiracetam258$13,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Restasis, Lumigan$122$65,68993 claims
MerckJanuvia$11$27,38549 claims
GileadVemlidy$47$25,23317 claims
UCB, Inc.Briviact$78$17,30412 claims
Boehringer IngelheimJardiance$59$13,71024 claims
GSKBreo Ellipta, Incruse Ellipta$19$13,18932 claims
Astellas Pharma US IncMyrbetriq$96$11,36025 claims
Johnson & JohnsonXarelto$116$7,34026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Drexel Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →